RojanPharma Pharmaceutical Company Report issue

For profit Phase 3
Founded: Tehran Iran (Islamic Republic of) (1925)
Status: No NME R&D (1925)

Organization Overview

First Clinical Trial
2017
NCT03369327
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

RojanPharma Pharmaceutical Company

Active Ingredients

Drugs in Phase 3 Trials (2)

daclatasvir (daklinza) (1 trial)

sofosbuvir (sovaldi) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 3)

Hepatitis (Phase 3)

Hepatitis A (Phase 3)

Hepatitis C (Phase 3)

HIV Infections (Phase 3)

Immunologic Deficiency Syndromes (Phase 3)

Virus Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 2